Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Eye Disease

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44380   clinical trials with a EudraCT protocol, of which   7392   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    783 result(s) found for: Eye Disease. Displaying page 20 of 40.
    «« First « Previous 16  17  18  19  20  21  22  23  24  Next» Last»»
    EudraCT Number: 2015-001266-26 Sponsor Protocol Number: GS-LHON-CLIN-03B Start Date*: 2016-01-21
    Sponsor Name:GENSIGHT-BIOLOGICS
    Full Title: A Randomized, Double-Masked, Sham-Controlled, Pivotal Clinical Trial to Evaluate the Efficacy of a Single Intravitreal Injection of GS010 (rAAV2/2-ND4) in Subjects Affected for more than 6 months a...
    Medical condition: Leber Hereditary Optic Neuropathy due to mutations in the mitochondrial NADH Dehydrogenase 4 gene
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-001405-90 Sponsor Protocol Number: GS-LHON/CLIN/01 Start Date*: 2013-12-26
    Sponsor Name:GENSIGHT-BIOLOGICS
    Full Title: A phase I/IIa, non randomized, escalating dose, open-label study to evaluate safety and efficacy of GS010 (rAAV2/2-ND4) in patients suffering from Leber Hereditary Optic Neuropathy due to mutations...
    Medical condition: Leber Hereditary Optic Neuropathy due to mutations in the mitochondrial NADH Dehydrogenase 4 gene
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004850 10062951 Leber's hereditary optic atrophy neuropathy LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-023111-34 Sponsor Protocol Number: SG1/001/10 Start Date*: 2011-07-18
    Sponsor Name:Oxford BioMedica (UK) Ltd
    Full Title: A Phase I/IIa Dose Escalation Safety Study of Subretinally Injected StarGen, Administered to Patients with Stargardt's Macular Degeneration.
    Medical condition: Stargardt Macular Dystrophy, also known as fundus flavimaculatus or Stargardt disease.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) NL (Not Authorised) IT (Prematurely Ended) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-000736-15 Sponsor Protocol Number: GLH694-P001 Start Date*: 2015-09-14
    Sponsor Name:Alcon Research, Ltd.
    Full Title: Additive Effect of Twice Daily Brinzolamide 1% /Brimonidine 0.2% Fixed Dose Combination as an Adjunctive Therapy to a Prostaglandin Analogue
    Medical condition: Ocular Hypertension Open-angle Glaucoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10030043 Ocular hypertension PT
    20.0 10015919 - Eye disorders 10030348 Open angle glaucoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) GB (Completed) FR (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2011-003816-21 Sponsor Protocol Number: RDG-10298 Start Date*: 2012-01-11
    Sponsor Name:S.A. Alcon-Couvreur N.V
    Full Title: Multi-Center Study Assessing Efficacy and Tolerability of TRAVATAN® Solution without BAK, containing Polyquad® Preservative (0.004% travoprost) in Patients Previously on latanoprost 0.005% or bimat...
    Medical condition: Open angle Glaucoma Ocular Hypertension
    Disease: Version SOC Term Classification Code Term Level
    14.0 10015919 - Eye disorders 10030043 Ocular hypertension PT
    14.0 10015919 - Eye disorders 10030348 Open angle glaucoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) SE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-003119-13 Sponsor Protocol Number: 14/0172 Start Date*: 2015-02-11
    Sponsor Name:Joint Research Office- UCL
    Full Title: Can simvastatin significantly reduce the amount of immunosuppressive medication required by patients with sight threatening uveitis? A phase IIb, single site, randomized, placebo controlled, double...
    Medical condition: Uveitis
    Disease: Version SOC Term Classification Code Term Level
    19.1 10021428 - Immune system disorders 10062016 Immunosuppression PT
    19.1 10015919 - Eye disorders 10046851 Uveitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-012564-13 Sponsor Protocol Number: Cystadrops®/09/choc-study Start Date*: 2013-01-03
    Sponsor Name:Orphan Europe SARL
    Full Title: Cysteamine Hydrochloride for nephropathic Cystinosis, open-label Phase III pivotal study
    Medical condition: Nephropatic cystinosis patients with cystine corneal deposits
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004850 10071112 Nephropathic cystinosis LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2017-004982-28 Sponsor Protocol Number: FFIS/PG/2017/03 Start Date*: 2018-05-23
    Sponsor Name:Fundación para la Formación e Investigación Sanitarias de la Región de Murcia
    Full Title: Phase IIb prospective, unicentric, randomized, parallel, double-blind, placebo-controlled clinical trial to evaluate the intravenous infusion of prostaglandins as therapy in patients with non-arter...
    Medical condition: Non-arteritic anterior ischemic optic neuropathy (NOIANA).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-002395-75 Sponsor Protocol Number: NSR-REP-02 Start Date*: 2018-01-17
    Sponsor Name:NightstaRx Ltd (A Biogen Company)
    Full Title: An Open-Label Safety Study of Retinal Gene Therapy for Choroideremia with Bilateral, Sequential Administration of Adeno-Associated Viral Vector (AAV2) Encoding Rab Escort Protein 1 (REP1)
    Medical condition: Choroideremia (CHM)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004853 10008791 Choroideremia LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2016-002531-15 Sponsor Protocol Number: 09/0959 Start Date*: 2016-11-14
    Sponsor Name:UCL Comprehensive Clinical Trials Unit
    Full Title: A phase II, open label, non-randomised, single centre, clinical trial of ANX776 in Healthy Volunteers and patients with Glaucoma, Age-Related Macular Degeneration, and Optic Neuritis
    Medical condition: Glaucoma, Age-related Macular Degeneration, and Optic Neuritis.
    Disease: Version SOC Term Classification Code Term Level
    19.0 10022891 - Investigations 10047560 Visual field perimetric tests LLT
    19.0 10015919 - Eye disorders 10018307 Glaucoma and ocular hypertension HLGT
    19.0 100000004867 10021948 Infiltration intravenous injection LLT
    19.0 10022891 - Investigations 10057208 Optical coherence tomography PT
    19.0 10015919 - Eye disorders 10071129 Neovascular age-related macular degeneration PT
    19.0 10015919 - Eye disorders 10064930 Age-related macular degeneration PT
    19.0 10022891 - Investigations 10047566 Visual field tests PT
    19.0 10015919 - Eye disorders 10009034 Chronic open angle glaucoma LLT
    19.0 10029205 - Nervous system disorders 10030942 Optic neuritis PT
    19.0 10015919 - Eye disorders 10006027 Borderline glaucoma PT
    19.0 10015919 - Eye disorders 10030043 Ocular hypertension PT
    19.0 10015919 - Eye disorders 10006028 Borderline glaucoma (glaucoma suspect) LLT
    19.0 10029205 - Nervous system disorders 10004571 Bilateral optic neuritis LLT
    19.0 10029205 - Nervous system disorders 10012121 Defect visual field (NOS) LLT
    19.0 100000004865 10020422 HRT LLT
    19.0 10015919 - Eye disorders 10018304 Glaucoma PT
    19.0 100000004865 10048541 Intravenous catheter management LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-004766-16 Sponsor Protocol Number: C-05-10 Start Date*: 2006-02-17
    Sponsor Name:Alcon Research, Ltd.
    Full Title: Comparison of Safety and Efficacy of Brinzolamide/Timolol Fixed Combination vs COSOPT in Patients with Open-Angle Glaucoma or Ocular Hypertension
    Medical condition: Open Angle Glaucoma or Ocular Hypertension ICD: H40.1/H40.0
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) BE (Completed) GB (Completed) LT (Completed) LV (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-015681-55 Sponsor Protocol Number: C-09-023 Start Date*: 2010-03-18
    Sponsor Name:Alcon Research, Ltd.
    Full Title: A Dose-Escalation Study of AL-39324 Suspension versus Lucentis™ for the Treatment of Exudative Age-Related Macular Degeneration
    Medical condition: Exudative Age-related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    14.0 10015919 - Eye disorders 10067791 Wet macular degeneration LLT
    14.0 10015919 - Eye disorders 10025409 Macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2017-001215-37 Sponsor Protocol Number: RG_16_211 Start Date*: 2018-03-19
    Sponsor Name:University of Birmingham
    Full Title: A pivotal, international, randomised, double-blind, efficacy and safety trial of sodium valporate in paediatric and adult patients with Wolfram Syndrome
    Medical condition: Wolfram syndrome
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) PL (Completed) FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-003193-17 Sponsor Protocol Number: BAY86-5321/17514 Start Date*: 2016-08-30
    Sponsor Name:Bayer AG
    Full Title: A multi center, single arm, interventional Phase 4 study to evaluate a Treat and Extend regimen of intravitreal aflibercept for treatment of macular edema secondary to central retinal vein occlusion
    Medical condition: Macular edema secondary to CRVO
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10025415 Macular oedema PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) DK (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-002611-99 Sponsor Protocol Number: 20090 Start Date*: Information not available in EudraCT
    Sponsor Name:Bayer AG
    Full Title: Open-label, randomized, two–arm, controlled study to assess the efficacy, safety, and tolerability of intravitreal (IVT) aflibercept compared to laser photocoagulation in patients with retinopathy ...
    Medical condition: Retinopathy of prematurity
    Disease: Version SOC Term Classification Code Term Level
    20.1 10015919 - Eye disorders 10038933 Retinopathy of prematurity PT
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: CZ (Completed) SE (Completed) NL (Completed) PT (Completed) GB (GB - no longer in EU/EEA) BE (Completed) DE (Completed) SK (Completed) AT (Completed) BG (Completed) PL (Completed) ES (Completed) HU (Completed) LT (Completed) EE (Completed) LV (Completed) GR (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2022-001092-14 Sponsor Protocol Number: TIGEM5_USH Start Date*: 2023-10-12
    Sponsor Name:FONDAZIONE TELETHON
    Full Title: A phase I/II open label, dose escalation study of sub-retinal administration of a “mixture of two adeno-associated viral vectors of serotype 8 containing the 5 ´- half sequence of the human MYO7A ...
    Medical condition: Usher syndrome (USH) is characterized by the association of sensorineural hearing loss, Retinitis Pigmentosa (RP), and, in some cases, vestibular dysfunction. It is the most frequent cause of deaf-...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10063396 Usher's syndrome PT
    20.0 10010331 - Congenital, familial and genetic disorders 10063396 Usher's syndrome PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-005081-19 Sponsor Protocol Number: 1 Start Date*: 2014-07-10
    Sponsor Name:HOSPICES CIVILS DELYON
    Full Title: Phase II study evaluating the efficacy of aflibercept for the treatment of idiopathic choroidal neovascularization in young subjects: the INTUITION study
    Medical condition: idiopathic choroidal neovascularization
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004853 10060837 Choroidal neovascularization LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-001247-51 Sponsor Protocol Number: v.1/040312 Start Date*: 2012-06-04
    Sponsor Name:Mika Harju
    Full Title:
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10006028 Borderline glaucoma (glaucoma suspect) LLT
    14.1 10015919 - Eye disorders 10037118 Pseudoexfoliation glaucoma LLT
    14.1 10015919 - Eye disorders 10036675 Primary angle-closure glaucoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2010-019975-30 Sponsor Protocol Number: 35131 Start Date*: 2010-08-24
    Sponsor Name:University Medical Center, Johannes Gutenberg-University Mainz
    Full Title: Investigation of the efficacy and safety of preoperative IOP reduction with preservative-free COSOPT-S® (dorzolamide/timolol, MSD) eye drops versus oral acetazolamide and dexamethasone eye drops an...
    Medical condition: Patients with glaucoma requiring trabeculectomy (filtration surgery)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10018304 Glaucoma LLT
    12.1 10050156 Glaucoma surgery LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-001469-28 Sponsor Protocol Number: SA2008 Start Date*: 2009-06-17
    Sponsor Name:Dep. of Ophthalmology, Medical University of Vienna
    Full Title: A randomized, double-masked study with intraocular Bevacizumab (Avastin®) compared with intravitreal Ranibizumab (Lucentis®) in patients with persistent diabetic macular edema or persistent active ...
    Medical condition: persistent diabetic macula edema or persistent diabetic proliferative retinopathy after lasercoagulation
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012689 Diabetic retinopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 16  17  18  19  20  21  22  23  24  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Feb 12 17:25:47 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA